SABS SAB Biotherapeutics
- 2.9700
- 0.00000.00%
SAB Biotherapeutics News
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 Loss per Share (Vs US$0.97 Loss in 3Q 2023)
Oppenheimer Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $12
SAB Biotherapeutics Price Target Maintained With a $25.00/Share by Chardan Capital
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for SAB Biotherapeutics' SAB-142 in Type 1 Diabetes Treatment Drives Buy Rating
SAB BIO Says Co Completed Phase 1 Enrollment For SAB-142 With No Observation Of Serum Sickness
SAB BIO Q3 2024 Cash, Cash Equivalents Available $30.4M-$56.6M
10-Q: Q3 2024 Earnings Report
Express News | SAB Biotherapeutics Inc- Qtrly Shr Loss $1.12
Express News | SAB Biotherapeutics Inc: Have Cash Sufficient to Fund Its Operations Into 2026
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Express News | SAB Bio Announces Third Quarter 2024 Financial Results and Provides Company Update
12 Health Care Stocks Moving In Friday's After-Market Session
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11
Express News | SAB Biotherapeutics : Craig-Hallum Initiates Coverage With Buy Rating and Target Price $11
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)
Analysis
Price Target
No Data
No Data